Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, Grossi F, Rindi G, Franciosi V, Ardizzoni A. Loprevite M, et al. Among authors: ardizzoni a. Clin Cancer Res. 2007 Nov 1;13(21):6518-26. doi: 10.1158/1078-0432.CCR-07-0805. Clin Cancer Res. 2007. PMID: 17975165
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A. Cascinu S, et al. Among authors: ardizzoni a. Br J Cancer. 2008 Jan 15;98(1):71-6. doi: 10.1038/sj.bjc.6604121. Epub 2007 Dec 4. Br J Cancer. 2008. PMID: 18059397 Free PMC article. Clinical Trial.
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Musolino A, et al. Among authors: ardizzoni a. J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17. J Clin Oncol. 2008. PMID: 18347005
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A. Tiseo M, et al. Among authors: ardizzoni a. Lung Cancer. 2010 Mar;67(3):355-60. doi: 10.1016/j.lungcan.2009.04.021. Epub 2009 May 26. Lung Cancer. 2010. PMID: 19473722
PTEN status in advanced colorectal cancer treated with cetuximab.
Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, Pedrazzi G, Ardizzoni A. Negri FV, et al. Among authors: ardizzoni a. Br J Cancer. 2010 Jan 5;102(1):162-4. doi: 10.1038/sj.bjc.6605471. Epub 2009 Dec 1. Br J Cancer. 2010. PMID: 19953097 Free PMC article.
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A, Boggiani D, Panebianco M, Vasini G, Salvagni S, Franciosi V, Ardizzoni A. Musolino A, et al. Among authors: ardizzoni a. Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19. Cancer. 2011. PMID: 20960528 Free article. Clinical Trial.
503 results